Clinical AdvancementsGalapagos continues to advance 3 clinical-stage CAR T programs in oncology with promising early efficacy and clean safety data, providing validation for its 7 day vein-to-vein POC CAR T platform.
Strategic CollaborationsThe FDA has cleared the IND to expand the ATALANTA trial to the U.S., and Galapagos has entered into a strategic collaboration to further expand its CAR-T production system.
Strategic LeadershipThe appointment of an activist investor to the board is seen as a potential catalyst for movement, as it was considered the right time to bring in an individual with strong connections in the biotech ecosystem.